These miniaturized “mini” or “micro” dystrophins can be engineered into an AAV vector, and several are the subjects of ongoing AAV-based gene therapy clinical trials in patients with DMD with the goal of rescuing the linkage between the actin cytoskeleton and the sarcolemmal dystroglycan complex (6). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.